HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Don’t Get Caught In Long-COVID OTC Painkiller ‘Hamster Wheel,’ Warn German Neurologists

Executive Summary

A significant proportion of COVID-19 headache sufferers go on to develop “new daily persistent headaches” syndrome. German neurologists warn that these people are at danger of medication overuse headaches, as well as kidney damage, as a result of taking OTC analgesics on a daily basis. 

You may also be interested in...



Inflation And COVID Putting Pressure On Europe’s Paracetamol Supply Chain

Inflation, new COVID-19 waves and delayed cold and flu outbreaks are causing disruption to Europe's paracetamol supply chain, according to an investigation by HBW Insight. Industry is not currently concerned, but regulators, for example in France, are introducing measures to prevent this issue spreading from children's to adult forms of the drug, as well as to ibuprofen-based alternatives.

Over The Counter 3 May 2022: Which COVID Trends Are Here To Stay? With IQVIA Consumer Health’s Prasanna Pitale

In this episode, HBW Insight talks to IQVIA Consumer Health’s Prasanna Pitale about the company's research on the recent self-care trends that will endure after COVID-19. Pitale points to wellness and prevention, Rx-to-OTC switch and naturals as drivers of long-term change in the global consumer health market. Sustainability and artificial intelligence are also noted as important disruptors that OTC companies need to act on if they are stay ahead of the pack in the years ahead.

Futura All Set For US FDA De Novo Application For Eroxon OTC ED Treatment

Futura Medical is preparing to seek approval from the FDA to launch OTC in the US its MED3000 erectile dysfunction treatment, marketed in Europe under the Eroxon brand name. After completing all the necessary studies demonstrating that the gel-based, drug-free product works as a self-care treatment for ED, Futura says it is confident that the soon to be submitted de novo medical device application will be successful and pave the way for a Q1 2023 launch.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel